Latest Metformin Stories
(Ivanhoe Newswire) -- Contradicting previous data, the use of vitamin E or the diabetes drug metformin, was not superior to placebo on a measured outcome for treating nonalcoholic fatty liver disease in children and adolescents, according to a new study."Coincident with the rise in prevalence of childhood and adolescent obesity over the past few decades, nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease in children in the United...
In contrast to previous preliminary data, use of vitamin E or the diabetes drug metformin was not superior to placebo on a measured outcome for treating nonalcoholic fatty liver disease in children and adolescents, according to a study in the April 27 issue of JAMA."Coincident with the rise in prevalence of childhood and adolescent obesity over the past few decades, nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease in children in the...
New research suggests that several commonly prescribed drugs for type 2 diabetes may not be as effective at preventing death and cardiovascular diseases, such as heart attacks and stroke, as the oral anti-diabetic drug, metformin.Insulin secretagogues (ISs), such as glimepiride, glibenclamide (known as glyburide in the USA and Canada), gliclazide and tolbutamide, have been used to treat type 2 diabetes since the 1950-1970s, Nevertheless, the long-term risk associated with these drugs has...
Research led by Warwick Medical School at the University of Warwick has found that Metformin, a drug treatment used to treat diabetes and also women with Polycystic Ovary syndrome (PCOS), may potentially provide protection against endometrial cancer.Endometrial cancer is the most common malignancy of the female genital tract and the fourth most common cancer in women in the UK and the US. Up to a third of PCOS women also have endometrial hyperplasia which, in turn predisposes these women to...
NEW YORK, March 16, 2011 /PRNewswire/ -- Get content from Novo Nordisk A/S at: http://www.thenewsmarket.com/Releases/StoryDetailPage.aspx?GUID=b0000cc7-5c54-43cf-b48c-91f48bdc1a68&lr=ls Novo Nordisk announced on March 15 that the Chinese State Food and Drug Administration (SFDA) has approved Victoza® for the treatment of type 2 diabetes. Victoza® is the brand name for liraglutide, the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue approved in China, developed for...
Johns Hopkins researchers examine newest medications, find they come up shortAn inexpensive type 2 diabetes drug that has been around for more than 15 years works just as well and has fewer side effects than a half-dozen other, mostly newer and more expensive classes of medication used to control the chronic disease, new Johns Hopkins research suggests.In their report, published online March 14 in the journal Annals of Internal Medicine, the Hopkins team found that metformin, an oral drug...
PARIS and LONDON, March 4, 2011 /PRNewswire-FirstCall/ -- In the news release, "ONGLYZA(R) Becomes the First DPP-4 Inhibitor Available for Use in Europe" issued on 4 Mar 2011 08:00 GMT, by Bristol-Myers Squibb and AstraZeneca NYSE:AZN over PR Newswire, we would like to advise that the headline was incorrectly transmitted by PR Newswire and should have read "ONGLYZA(R) Becomes the First DPP-4 Inhibitor Available for Use in Europe in Type 2 Diabetes Patients With Moderate or Severe Renal...
PARIS and LONDON, March 4, 2011 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (http://www.bms.com)(NYSE: BMY) and AstraZeneca (http://www.astrazeneca.com) (NYSE: AZN)today announced that the European Commission has approved a label update for ONGLYZA(R) (saxagliptin) in the treatment of adults with type 2 diabetes who have moderate or severe renal impairment. The approved dosage for the patient group is a new once-daily 2.5 mg dose. ONGLYZA will be the first dipeptidyl...
DEERFIELD, Ill. and OSAKA, Japan, Dec. 21, 2010 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc. ("TPNA"), have completed settlements with all defendants in patent litigation brought against the companies in response to their Abbreviated New Drug Applications ("ANDAs") for generic ACTOS® (pioglitazone HCl), ACTOplus met® (pioglitazone HCl and metformin HCl), and...
Scientists from Berlin, Bonn and Dundee show in animal models that the diabetes drug Metformin has an effect against one of the main causes of the Alzheimer's disease.Bonn, 24th November 2010. Metformin, a drug used in type 2-diabetes might have the potential to also act against Alzheimer's disease. This has been shown in a study from scientists of the German Center for Neurodegenerative Diseases (DZNE), the University of Dundee and the Max-Planck-Institute for Molecular Genetics. The...
